Barinthus Biotherapeutics PLC
NASDAQ:BRNS

Watchlist Manager
Barinthus Biotherapeutics PLC Logo
Barinthus Biotherapeutics PLC
NASDAQ:BRNS
Watchlist
Price: 0.6779 USD -3.54% Market Closed
Market Cap: 27.7m USD

Barinthus Biotherapeutics PLC
Tax Provision

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Barinthus Biotherapeutics PLC
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Barinthus Biotherapeutics PLC
NASDAQ:BRNS
Tax Provision
$44k
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Tax Provision
-$2.8m
CAGR 3-Years
-196%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Tax Provision
$2.2m
CAGR 3-Years
6%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Tax Provision
£1.9m
CAGR 3-Years
-42%
CAGR 5-Years
-39%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Tax Provision
-£9.2m
CAGR 3-Years
8%
CAGR 5-Years
3%
CAGR 10-Years
6%
Oxford BioMedica PLC
LSE:OXB
Tax Provision
-£1.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Barinthus Biotherapeutics PLC
Glance View

Market Cap
27.7m USD
Industry
Biotechnology

Vaccitech Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 107 full-time employees. The company went IPO on 2021-04-30. The company is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. The company is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.

BRNS Intrinsic Value
Not Available

See Also

What is Barinthus Biotherapeutics PLC's Tax Provision?
Tax Provision
44k USD

Based on the financial report for Dec 31, 2024, Barinthus Biotherapeutics PLC's Tax Provision amounts to 44k USD.

What is Barinthus Biotherapeutics PLC's Tax Provision growth rate?
Tax Provision CAGR 3Y
16%

Over the last year, the Tax Provision growth was -99%. The average annual Tax Provision growth rates for Barinthus Biotherapeutics PLC have been 16% over the past three years .

Back to Top